Status:
COMPLETED
Study of LY3074828 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate different concentrations and formulations of LY3074828 compared to placebo ("dummy drug"). The study will consist of 2 parts: Part A and Part B. Screening is ...
Eligibility Criteria
Inclusion
- \- Have venous access sufficient to allow for blood sampling and administration of investigational product
Exclusion
- Must not have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females)
- Must not show evidence of active or latent tuberculosis (TB)
- Must not have received live vaccine(s) (including attenuated live vaccines and those administered intranasally) within 1 month of screening or intend to receive during the study
- Must not be immunocompromised
- Must not have known hypersensitivity to hyaluronidases
- Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
- Must not have significant allergies to humanized monoclonal antibodies
- Must not have clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions
- Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
- Must not have had breast cancer within the past 10 years
Key Trial Info
Start Date :
October 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 18 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03748940
Start Date
October 10 2018
End Date
June 18 2019
Last Update
July 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Ltd
Leeds, West Yorkshire, United Kingdom, LS2 9LH